# US 2021/0263052 A1 · Blood coagulation system analysis device

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0263052 A1
- Document ID: US20210263052A1
- Status: Published application
- Kind: A1
- Application number: 17/260,969
- Filed: 2019-06-12
- Published: 2021-08-26
- Earliest claimed: 2018-07-25
- Assignees: Sony Corporation
- Applicants: Sony Corporation
- Inventors: Yoshihito Hayashi; Tokujiro Uchida; Yudai Yamamoto
- Web page: https://patentgrep.com/patent/US20210263052A1

## CPC

- G01N 33/5438: {Electrodes}
- G01N 33/86: involving blood coagulating time {or factors, or their receptors}
- G01N 27/228: {Circuits therefor (measuring capacitance per se G01R27/26)}
- G01N 2333/7454: Tissue factor (tissue thromboplastin, Factor III)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

To provide a blood coagulation system analysis device capable of easily and rapidly evaluating a human tissue factor pathway inhibitor. A blood coagulation system analysis device provided with a pair of electrodes, an application unit that applies an alternating voltage to the pair of electrodes at a predetermined time interval, a measurement unit that measures complex permittivity of a blood sample arranged between the pair of electrodes, and an analysis unit that evaluates a human tissue factor pathway inhibitor (TFPI) on the basis of the complex permittivity at a specific frequency in a predetermined period measured at the time interval after anticoagulant action acting on the blood sample is released.

## Claims

### Claim 1

A blood coagulation system analysis device comprising:
a pair of electrodes;
an application unit that applies an alternating voltage to the pair of electrodes at a predetermined time interval;
a measurement unit that measures complex permittivity of a blood sample arranged between the pair of electrodes; and
an analysis unit that evaluates a human tissue factor pathway inhibitor (TFPI) on a basis of the complex permittivity at a specific frequency in a predetermined period measured at the time interval after anticoagulant action acting on the blood sample is released.

### Claim 2 (depends on 1)

The blood coagulation system analysis device according to claim 1, wherein the TFPI is evaluated by using a tissue factor and an anti-TFPI antibody.

### Claim 3 (depends on 2)

The blood coagulation system analysis device according to claim 2, wherein the analysis unit evaluates the TFPI on a basis of the complex permittivity measured by using the tissue factor and the anti-TFPI antibody and the complex permittivity measured by using the tissue factor.

### Claim 4 (depends on 2)

The blood coagulation system analysis device according to claim 2, wherein a heparin decomposing agent and/or a heparin neutralizing agent are further used.

### Claim 5 (depends on 4)

The blood coagulation system analysis device according to claim 4, wherein the analysis unit evaluates the TFPI on a basis of the complex permittivity measured by using the tissue factor, the heparin decomposing agent and/or the heparin neutralizing agent, and the anti-TFPI antibody, and the complex permittivity measured by using the tissue factor and the heparin decomposing agent and/or the heparin neutralizing agent.

### Claim 6 (depends on 1)

The blood coagulation system analysis device according to claim 1, wherein a feature amount extracted from a complex permittivity spectrum at the specific frequency is used at the time of the evaluation.

### Claim 7 (depends on 6)

The blood coagulation system analysis device according to claim 6, wherein the feature amount is a time feature amount and/or a gradient feature amount extracted from the complex permittivity spectrum at the specific frequency.

### Claim 8 (depends on 7)

The blood coagulation system analysis device according to claim 7, wherein the gradient feature amount is extracted on a basis of the time feature amount extracted from the complex permittivity spectrum at the specific frequency.

### Claim 9 (depends on 6)

The blood coagulation system analysis device according to claim 6, wherein the feature amount is any one or more selected from a group including time CT0 at which a local maximum value of the complex permittivity is given at a low frequency of 100 kHz or higher and lower than 3 MHz, time CT1 at which a maximum gradient is given at the low frequency, a maximum gradient CFR at the low frequency, time CT4 when an absolute value of the gradient reaches a predetermined percentage of the CFR after the CT1, time CT at which a local minimum value of the complex permittivity is given at a high frequency of 3 to 30 MHz, time CT3 at which a maximum gradient is given at the high frequency, a maximum gradient CFR2 at the high frequency, time CT2 at which an absolute minimum value of the complex permittivity is given when a straight line is drawn at the gradient of CFR2 from CT3 after the CT and before the CT3, and time CT5 when an absolute value of the gradient reaches a predetermined percentage of the CFR2 after the CT3.

### Claim 10 (depends on 1)

The blood coagulation system analysis device according to claim 1, wherein the analysis unit analyzes a degree of postoperative bleeding risk.

### Claim 11 (depends on 10)

The blood coagulation system analysis device according to claim 10, wherein the bleeding risk is a bleeding amount.

### Claim 12 (depends on 1)

The blood coagulation system analysis device according to claim 1, further comprising:
one or a plurality of electrical measurement containers including an assay that at least evaluates extrinsic coagulation ability.
